bodyType

customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

hooksAmpRedirectArticle

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

paywallTypes

createdDate

publishedDate

urlAlias

moreOnThisArticles

sponsorType

commentCount

authorLocations

authors

corrections

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

articleSpeeches

socialHeadline

headline

images

flag

firstTopic

glossary

flattenTypeIds

image

relatedLinks

relatedNewsletters

__typename

sponsor

pdfFiles

seriesReverseOrder

series

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

readingTime

customTimezone

liveContents

Agence France-Presse

The US has begun late stage clinical trials into a drug formulated to fight Covid-19, officials said Tuesday.
The medicine is an antibody against the new coronavirus called LY-CoV555, which was identified in the blood sample of a recovered patient by Canada’s Abcellera Biologics.
It was then developed synthetically for mass production by US-based Lilly Research Laboratories in partnership with Abcellera.
The Phase 3 trial will initially enrol some 300 volunteers around the world who have been hospitalised with mild to moderate Covid-19 with fewer than 13 days of symptoms.


Each will be assigned either the medicine, which will be injected intravenously, or a placebo.
Patients will also receive standard care for Covid-19, including the antiviral remdesivir.
The new Phase 3 trial is being led by Jens Lundgren, of the University of Copenhagen and Rigshospitalet, and could expand to up to 1,000 people, including the more severely ill, if LY-CoV555 appears safe and effective after the fifth day.
Hong Kong, Macau researchers to start clinical trials of Covid-19 vaccine
The trial’s main goal is the patients’ sustained recovery for 14 days after release from the hospital.
At the same time, the new drug is also being tested on people with mild to moderate symptoms of Covid-19 who have not been hospitalised, as part of a parallel middle-stage trial also announced Tuesday.

“Studying the impact of this investigational therapeutic on multiple patient populations at the same time is critical to determining whether it can help Covid-19 patients with differing levels of disease severity,” said Anthony Fauci, director of the National Institutes of Allergies and Infectious Diseases.
Antibodies are infection-fighting proteins made by the immune system that can bind to the surface of viruses and prevent them from invading cells.
Vaccines work by teaching the body to make its own antibodies, while scientists are also testing ready-made antibodies from the blood of recovered patients, called convalescent plasma.
But it is not possible to make convalescent plasma a mass treatment.
Researchers can also comb through the antibodies produced by recovered patients and select the most effective out of thousands, and then manufacture it at scale.



Hong Kong’s Peninsula Hotels sees ‘bleisure’ boom after pandemic curbs, CEO says

US could require US$15,000 bonds for some tourist, business visas

China’s Shenzhen, Guangzhou airports hit record highs, surpass pre-Covid passenger levels

Landmark US Chinatown survived Covid, anti-Asian violence – but tariffs pose new threat

Coronavirus pandemic

Coronavirus: US announces major clinical trial of antibody treatment

A researcher tests possible Covid-19 antibodies in a laboratory in Indianapolis. Photo: Eli Lilly via AP

(FILES) This undated file handout image obtained July 15, 2020, courtesy of National Institute of Allergy and Infectious Diseases(NIH/NIAID), shows a transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient, captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. - The US has begun late stage clinical trials into a drug formulated to fight COVID-19, officials said on August 4, 2020. The medicine is an antibody against the new coronavirus called LY-CoV555, which was identified in the blood sample of a recovered patient by Canada's Abcellera Biologics. It was then developed synthetically for mass production by US-based Lilly Research Laboratories in partnership with Abcellera. (Photo by Handout / National Institute of Allergy and Infectious Diseases / AFP) / RESTRICTED TO EDITORIAL USE - MANDATORY CREDIT "AFP PHOTO /NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES/HANDOUT " - NO MARKETING - NO ADVERTISING

Coronavirus: researchers from Hong Kong, Macau, mainland China hope to start clinical trials of vaccine in months

Researchers from Hong Kong and Macau have developed a vaccine that stops a key part of the infection process by preventing the coronavirus from attaching itself to human cells. Photo: AP

(L-R)Professor Johnson Lau, Professor Alexander Wai, Professor Manson Fok and Professor Zhang Kang revealed the vaccine developed by scientists at PolyU and Macau University of Science and Technology on Monday. Photo: Hong Kong Polytechnic University

This undated electron microscope image made available by the U.S. National Institutes of Health in February 2020 shows the Novel Coronavirus SARS-CoV-2. Also known as 2019-nCoV, the virus causes COVID-19. The sample was isolated from a patient in the U.S. (NIAID-RML via AP)

Coronavirus: Chinese customs stalls vaccine shipment for trials in Canada

Canada has agreed to host clinical trials of a potential coronavirus vaccine developed by China’s CanSino Biologics. Photo: CanSino Biologic s

News

World

United States & Canada

Coronavirus

US & Canada

Health & Medicine


The trial will initially enrol some 300 volunteers who have all had the virus
The treatment has been developed by US-based Lilly Research Laboratories in partnership with Abcellera



Coronavirus: US announces major clinical trial of antibody treatment

The trial will initially enrol some 300 volunteers who have all had the virus The treatment has been developed by US-based Lilly Research Laboratories in partnership with Abcellera

The trial will initially enrol some 300 volunteers who have all had the virus

The treatment has been developed by US-based Lilly Research Laboratories in partnership with Abcellera